Evidence map›Paper›PMID 42004220›Full record

ArticleGenes & diseases2026

Blockade of co-inhibitory receptor immune checkpoint protein TIM3/CD366 augments the anti-cancer activity of CAR-T therapy in solid tumors: An ovarian cancer example.

Binglan Zhang, Fuping Zhu, Song Wang, Yong Huang, Shishi Yu, Shaorong Tian, Minmin Li, Pan Li, Qian Xue, Bingqiang Zhang

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Genes & diseases, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Binglan ZhangDepartment of Gastroenterology, The First Affiliated Hospital of Chongqing Medical University, Chongqing 400016, China.
Fuping ZhuDepartment of Hepatobiliary Surgery, The Ninth People's Hospital of Chongqing, Chongqing 400700, China.
Song WangDepartment of Gastroenterology, The First Affiliated Hospital of Chongqing Medical University, Chongqing 400016, China.
Yong HuangDepartment of Biotherapy, State Key Laboratory of Biotherapy and Cancer Center, West China Hospital, Sichuan University, Chengdu, Sichuan 610041, China.
Shishi YuDepartment of Gastroenterology, Chongqing Key Laboratory of Translational Research for Cancer Metastasis and Individualized Treatment, Chongqing University Cancer Hospital, Chongqing 400030, China.
Shaorong TianDepartment of Gastroenterology, The First Affiliated Hospital of Chongqing Medical University, Chongqing 400016, China.
Minmin LiDepartment of Oncology, The First Affiliated Hospital of Chongqing Medical University, Chongqing 400016, China.
Pan LiDepartment of Gastroenterology, The First Affiliated Hospital of Chongqing Medical University, Chongqing 400016, China.
Qian XueDepartment of Gastroenterology, The First Affiliated Hospital of Chongqing Medical University, Chongqing 400016, China.
Bingqiang ZhangDepartment of Gastroenterology, University-Town Hospital of Chongqing Medical University, Chongqing 401331, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Strategies that enhance the function of chimeric antigen receptor-modified T (CAR-T) cells for solid tumors are critical. Inhibitory immuno-checkpoints blockade could potentially enhance CAR-T cell function. TIM-3 is an important negative regulator of T cell activity, but whether TIM-3 blockade could affect CAR-T cell function remains unclear. In our study, we successfully constructed TIM-3-silenced CAR-T cells by dual-promoter lentivirus vectors that simultaneously express the TIM-3 targeting short hairpin RNA (shRNA) and a third-generation CAR recognizing HER2. We demonstrated that down-regulation of TIM-3 did not affect the phenotype of CAR-T cells. CAR-T cells with TIM-3 blockade exhibited higher lytic cytotoxicity to target cells

Indexed as

Cell therapyChimeric antigen receptorImmunotherapyInhibitory checkpointTIM-3

Identifiers

PMID42004220
PMCPMC13084341

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.